Clinical Trial Update: A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of LW231 in healthy volunteers and participants with chronic hepatitis B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• LW231

Snippet

Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. | Conditions: Chronic Hepatitis B | Phase 1 | Status: COMPLETED